Statistical models for longitudinal biomarkers of disease onset

Statistics in Medicine

Volumn 19, Issue 4, 2000, Pages 617-637

  Slate, Elizabeth H ^a   Turnbull, Bruce W ^a  

^a Cornell University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; PROSTATE SPECIFIC ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER DIAGNOSIS; CANCER SCREENING; CONFERENCE PAPER; CONTROLLED STUDY; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; PROBABILITY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL MODEL;

ALGORITHMS; BAYES THEOREM; BIOLOGICAL MARKERS; HUMANS; LONGITUDINAL STUDIES; MALE; MODELS, STATISTICAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ROC CURVE;

EID: 0034728376     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0258(20000229)19:4<617::AID-SIM360>3.0.CO;2-R     Document Type: Conference Paper

References (63)

1. Tate H. A Bayesian approach to the analysis of serial tumour-marker data. Statistician 1983; 32:116.
2. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. Journal of the American Medical Association 1992; 267(16): 2215-2220.
3. Carter HB, Epstein JI, Chan DW, Fozard JL, Pearson JD. Recommended prostate-specific antigen testing intervals for the detection of cureable prostate cancer. Journal of the American Medical Association 1997; 277(18): 1456-1460.
4. Prentice RL, Kalbfleisch JD, Peterson AV, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics 1978; 34:541-554.
5. Gail MH. Evaluating serial cancer marker studies in patients at risk of recurrent disease. Biometrics 1981; 37:927-936 (correction: 42, 229).
6. Lin DY, Fleming TR, De Gruttola V. Estimating proportion of treatment effect explained by a surrogate marker. Statistics in Medicine 1997; 16:1515-1527.
7. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. Wiley: New York, 1980.
8. Jewell NP, Nielsen JP. A framework for consistent prediction rules based on markers. Biometrika 1993; 80:153-164.
9. Tsiatis AA, De Gruttola V, Wulfsohn M. Modeling the relationship of survival to longitudinal data measured with error. Applications to survival and CD4 counts in patients with AIDS. Journal of the American Statistical Association 1995; 90:27-37.
10. De Gruttola V, Tu XM. Modelling progression of CD4-lymphocyte count and its relationship to survival time. Biometrics 1994; 50:1003-1014.
11. Wu MC, Carroll RJ. Estimation and comparison of changes in the presence of informative right censoring: modeling the censoring process. Biometrics 1988; 44:175-188.
12. Schluchter MD. Methods for the analysis of informatively censored longitudinal data. Statistics in Medicine 1992; 11:1861-1870.
13. Hogan JW, Laird NM. Mixture models for the joint distribution of repeated measures and event times. Statistics in Medicine 1997; 16:239-257.
14. Hogan JW, Laird NM. Model-based approaches to analysing incomplete longitudinal and failure time data. Statistics in Medicine 1997; 16:259-272.
15. Pawitan Y, Self S. Modeling disease marker processes in AIDS. Journal of the American Statistical Association 1993; 88:719-726.
16. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38:963-974.
17. Taylor JMG, Cumberland WG, Sy JP. A stochastic model for analysis of longitudinal AIDS data. Journal of the American Statistical Association 1994; 89:727-736.
18. Jewell NP, Kalbfleisch JD. Marker processes in survival analysis. Lifetime Data Analysis 1996; 2:15-29.
19. Shi M, Taylor JMG, Munoz A. Models for residual time to AIDS. Lifetime Data Analysis 1996; 2:31-49.
20. Day R, Bryant J, Lefkopoulou M. Adaptation of bivariate frailty models for prediction, with application to biological markers as prognostic indicators. Biometrika 1997; 84:45-56.
21. Klein JP, Klotz JH, Grever MR. A biological marker model for predicting disease transitions. Biometrics 1984; 40:927-936.
22. Hsieh FY, Crowley J, Tormey DC. Some test statistics for use in multistate survival analysis. Biometrika 1983; 70:111-119.
23. Myers LE, Paulson DF, Berry WR, Cox EB, Laszlo J, Stanley W. A time-dependent statistical model which relates current clinical states to prognosis: application to advanced prostatic cancer. Journal of Chronic Diseases 1980; 33:491-499.
24. Kay R. A Markov model for analysing cancer markers and disease states in survival studies. Biometrics 1986; 42:855-865.
25. Satten GA, Longini IA. Markov chains with measurement error: estimating the 'true' course of a marker of the preogression of human immunodeficiency virus disease (with discussion). Applied Statistics 1996; 45:275-309.
26. Page ES. A test for a change in a parameter occurring at an unknown point. Biometrika 1955; 42:523-527.
27. Hinkley DV. Inference about the intersection in two-phase regression. Biometrika 1969; 56:495-504.
28. Hinkley DV. Inference about the change-point in a sequence of random variables. Biometrika 1970; 57:1-17.
29. Smith AFM. A Bayesian approach to inference about a change-point in a sequence of random variables. Biometrika 1975; 62:407-416.
30. Carlin BP, Gelfand AE, Smith AFM. Hierarchical Bayesian analysis of changepoint problems. Applied Statistics 1992; 41:389-405.
31. Stephens DA. Bayesian retrospective multiple-changepoint identification. Applied Statistics 1994; 43:159-178.
32. MacDonald IL, Zucchini W. Hidden Markov and Other Models for Discrete-Valued Time Series. Chapman and Hall: New York, 1997.
33. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. New England Journal of Medicine 1991; 324(17): 1156-1161.
34. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. Journal of the American Medical Association 1993; 270(8): 948-954.
35. American Cancer Society. Prostate Cancer Detection Guidelines. American Cancer Society: 1997.
36. Whittemore AS, Lele C, Friedman GC, Stamey T, Vogelman JJ, Orentreich N. Prostate-specific antigen as predictor of prostate cancer in black men and white men. Journal of the National Cancer Institute 1995; 87(5): 354-360.
37. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM. Serum prostate-specific antigen in a community-based population of healthy men. Journal of the American Medical Association 1993; 270(5):660-664.
38. Pearson JD, Morrell CH, Landis PK, Carter HB, Brant LJ. Mixed-effects regression models for studying the natural history of prostate disease. Statistics in Medicine 1994; 13:587-601.
39. Clark LC, Combs GF, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL, Park HK, Sanders BB, Smith CL, Taylor JR and the Nutritional Prevention of Cancer Study Group. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: A randomized clinical trial. Journal of the American Medical Association 1996; 276(24): 1957-1963.
40. Cleveland WS, Devlin SJ. Locally-weighted regression: an approach to regression analysis by local fitting. Journal of the American Statistical Association 1988; 83:596-610.
41. McLaughlin PW, Sandier HM, Jiroutek MR. Prostate-specific antigen following prostate radiotherapy: how low can you go? Journal of Clinical Oncology 1996; 14(11):2889-2892.
42. Slate EH, Cronin KA. Changepoint modeling of longitudinal PSA as a biomarker for prostate cancer. In Case Studies in Bayesian Statistics III, Gatsonis C, Hodges JS, Kass RE, McCulloch R, Rossi P. Singpurwalla ND (eds). Springer-Verlag: New York, 1997; 444-456.
43. Lindstrom MJ, Bates DM. Newton-Raphson and EM algorithm for linear mixed-effects models for repeated-measures data. Journal of the American Statistical Association 1988; 83:1014-1022.
44. Lindstrom MJ, Bates DM. Nonlinear mixed effects models for repeated measures data. Biometrics 1990; 46:673-687.
45. Seber GAF, Wild CJ. Nonlinear Regression. Wiley: New York, 1989.
46. Morrell CH, Pearson JD, Carter HB, Brant LJ. Estimating unknown transition times using a piecewise nonlinear mixed-effects model in men with prostate cancer. Journal of the American Statistical Association 1995; 90:45-53.
47. Lange N, Carlin BP, Gelfand AE. Hierarchical Bayes models for the progression of HIV infection using longitudinal CD4 T-cell numbers (with discussion). Journal of the American Statistical Association 1992; 87:615-632.
48. Cronin KA, Slate EH, Turnbull BW, Wells MT. Using the Gtbbs sampler to detect changepoints: application to PSA as a longitudinal marker for prostate cancer. Computing Science and Statistics 1994; 26:314-318.
49. Slate EH, Clark LC. Using PSA to detect prostate cancer onset: an application of Bayesian retrospective and prospective changepoint identification. Case Studies in Bayesian Statistics IV 1998; 511-534.
50. Press SJ. Applied Multivariate Analysis: Using Bayesian and Frequentist Methods of Inference. Robert E. Krieger Publishing: New York, 1982.
51. Geman S, Geman D. Stochastic relaxation, Gibbs distributions, and the Bayesian restoration of images. IEEE Transactions on Pattern Analysis and Machine Intelligence 1984; 6:721-741.
52. Gelfand AE, Smith AFM. Sampling-based approaches to calculating marginal densities. Journal of the American Statistical Association 1990; 85:398-409.
53. Cronin KA. Detection of changepoints in longitudinal data. PhD Dissertation, Cornell University, 1995.
54. Emir B, Wieand S, Su JQ, Cha S, Analysis of repeated markers used to predict progression of cancer, Statistics in Medicine 1998; 17:2563-2578.
55. Murtaugh PA. ROC curves with multiple marker measurements. Biometrics 1995; 51:1514-1522.
56. Gulyas SW, Slate EH, Turnbull BW. Fitting latent changepoint models for serial biomarkers using the EM algorithm. Computing Science and Statistics 1997; 29:253-258.
57. Gulyas SW, Slate EH, Turnbull BW. Latent changepoint process models for longitudinal biomarkers of disease. Proceedings of the Biometrics Section 1997; 249-252.
58. Dempster AP, Laird NM, Rubin DB. Maximum likelihood from incomplete data via the EM algorithm. Journal of the Royal Statistical Association Series B 1977; 39:1-22.
59. Orchard T, Woodbury MA. A missing information principle: theory and applications. Proceedings of the Sixth Berkeley Symposium on Mathematical Statistics 1972; 1:697-715.
60. Louis TA. Finding observed information using the EM algorithm. Journal of the Royal Statistical Society Series B 1982; 44:98-130.
61. Meng XL, Rubin DB. Using EM to obtain asymptotic variance-covariance matrices. Journal of the American Statistical Association 1991; 86:899-909.
62. Tanner MA. Tools for Statistical Inference: Methods for the Exploration of Posterior Distribution and Likelihood Functions, 2nd edn, Springer-Verlag: New York, 1993.
63. Gulyas SW. Latent disease changepoint models for longitudinal biomarkers. PhD Dissertation, Cornell University, 1998.